ProQR Therapeutics (PRQR)
ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP
ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP
Amneal Pharmaceuticals, Inc. - Amneal Releases 2024 Responsible Business Report
Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements
Aethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate Update
Labcorp to Announce Second Quarter Financial Results on July 24, 2025
INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on M
Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025
Windtree Advances Lower Cost Manufacturing of PHEXXI,Evofem’s Hormone-Free, On-Demand Prescription Contraceptive Gel
Alto Ingredients, Inc. Names Gilbert Nathan Chair, Dianne Nury Vice-Chair and Elects Two New Directors
Aclaris Therapeutics to Participate in the H.C.Wainwright Inflammation & Immunology Virtual Conference